Drug Development
SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Michael.
Clinical Performance of the APTIMA HPV Assay for Detection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens C. Hill 1, J. Dockter.
Emerging Issues with Adaptation of Clinical Trial Design in Drug Development* H.M. James Hung Division of Biometrics I, Office of Biostatistics, OPaSS,
Clinical Evaluation of Preventive Vaccines: Use of Bridging Studies Marion F. Gruber, Ph.D. 2006 FDA/Industry Statistics Workshop Washington D.C., September.
2006 FDA/Industry Workshop Advantages and Challenges of Bayesian Clinical Trials Increased Bayesian Submissions: A future state of Drug applications? Stacy.
Optimal Antifungal Prophylaxis The Case for Posaconazole Oliver A. Cornely, MD, FIDSA Dep. I for Internal Medicine Hematology - Oncology Infectious Diseases.
Introduction to Toxicology A Brief Introduction to the Concepts of Toxicology We Will Be Using Throughout This Course.
OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.
Non-colon › Esophagogastric › Pancreatic › Hepatobiliary.
Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery G. Montalescot,
